Semantic Scholar uses AI to extract papers important to this topic.
We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent… Expand PURPOSE
To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma.
PATIENTS AND METHODS
Patients… Expand PURPOSE
The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We… Expand BACKGROUND
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and… Expand BACKGROUND
The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer… Expand PURPOSE
Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil… Expand BACKGROUND
The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal… Expand BACKGROUND
Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We… Expand BACKGROUND
In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been… Expand